Aug. 21 at 6:12 PM
$ACHV Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
BENZINGA 1:11 PM ET 8/21/2025
Achieve Life Sciences Inc. (ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026.
In a vote of confidence for the late-stage specialty pharmaceutical company’s pipeline with a focus on smoking health and nicotine dependence, HC Wainwright has initiated coverage on Achieve Life Sciences(ACHV) with a Buy rating and a
$12 price forecast.
In June, Achieve Life Sciences(ACHV) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cytisinicline for nicotine dependence for smoking cessation in adults.
